VivoSim Labs shares surge 75.59% intraday after appointing JCBio in Korea and Tekon Biotech in China as distributors to expand NAMKind toxicology services in Asia-Pacific with 30-day compound turnaround.

VivoSim Labs surged 75.59% in intraday trading, following the announcement of appointing JCBio in South Korea and Tekon Biotech in China as authorized distributors to expand NAMKind™ human liver and intestinal toxicology services across the Asia-Pacific region. The move aims to address regional demand for rapid, human-relevant toxicology solutions with a 30-day turnaround per compound.